Bradlee Heckmann

Company: Asha Therapeutics

Job title: Chief Scientific Officer

Seminars:

Panel Discussion: How Are Regulators & Industry Thinking About Degraders from a Safety Perspective in 2025? 10:00 am

What if anything has changed on the FDA side with regards regulation of degraders? What is the pre-clinical and clinical data telling us thus far for degraders? Where are the opportunities for collaboration between stakeholders to drive these needs forward?Read more

day: Day One AM